Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: kenhott who wrote (9929)	1/31/2007 2:56:28 PM
From: Icebrg	Read Replies (1) \| Respond to of 10280

Yes, they said they intend to repay the debt. On February 14, 2000, Sepracor issued $400,000,000 in principal amount of 5% Convertible Subordinated Debentures due 2007 (the "5% Debentures"). The 5% Debentures have an annual interest of 5% and are convertible into Sepracor Common Stock at $92.38 per share. On March 9, 2000, Sepracor issued an additional 60,000,000 in principal amount of 5% Debentures pursuant to an option granted to the initial purchaser of the 5% Debentures. Sepracor intends to use the proceeds from the sale of the 5% Debentures for its ongoing preclinical and clinical trials, expansion of sales and marketing capabilities, funding of other research and development programs, working capital and other general corporate purposes.